As the pathogenesis of CAPS including CINCA is not limited in the lamina propria (25–27), whether this PTPN22-mediated NLRP3 phosphorylation can suppress CAPS and other NLRP3-driven disorders is still unclear. The gene discussed is PTPN22; the disease is cryopyrin-associated periodic syndrome.